No Data
No Data
Earnings Preview: MNMD to Report Financial Results Post-market on November 07
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update
FDA Is Said to See "Path Forward" for Ecstasy-based Drug
Bright Minds Rally Ends as Psychedelic Stocks Extend Volatility
Leerink Partners Initiates Mind Medicine(MNMD.US) With Buy Rating, Announces Target Price $20
Mind Medicine: A Strong Buy on Financial Health and Growth Prospects
No Data
No Data